- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03918967
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants
June 7, 2020 updated by: Celltrion
A Two-segment Phase I, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G11 and CT-G20 in Healthy Volunteers (Part 1 and Part 2) and Open Label, Balanced, Randomized, Two-period, Two-Sequence Crossover Study to Assess the Effect of Food on the Pharmacokinetics of CT-G20 in Healthy Volunteers (Part 3)
The purpose of this study is to establish safety, tolerability, pharmacokinetics and pharmacodynamics of CT-G20 or CT-11 and to evaluate potential effect of food on pharmacokinetics of CT-G20 in human participants. It will be conducted in three parts, as described below:
- Part I will be a randomized, double-blind, placebo-controlled, sequential, single ascending dose study.
- Part II will be a randomized, double-blind, placebo-controlled, sequential, multiple ascending dose study.
- Part III will be a randomized, open-label, balanced, two-period, two-sequence crossover, food effect study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- body mass index (BMI) ≥18.0 and ≤30.0 kg/m2
Exclusion Criteria:
- Clinically significant allergic reactions
- Gastrointestinal, renal, hematological, metabolic, neurologic or pulmonary diseases classified as significant by the Investigator
- Hepatic dysfunction upper limit of normal laboratory range
- Cardiac history or presence
- History or any concomitant active malignancy
- A known infection with human immunodeficiency virus, hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Inherited bleeding diathesis or coagulopathy with the risk of bleeding
- Hemoptysis, thrombotic or hemorrhagic event
- Cerebral vascular accident, transient ischemic attack, or subarachnoid hemorrhage
- History and/or sign/symptoms of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
- Lactose intolerance (lactase deficiency) and glucose-galactose malabsorption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CT-G11
CT-G11 Experimental Drug
|
oral tablet of CT-G11 Experimental Drug
|
Experimental: CT-G20
CT-G20 Experimental Drug
|
oral tablet of CT-G20 Experimental Drug
|
Placebo Comparator: CT-G11 Placebo
|
oral tablet of Placebo
|
Placebo Comparator: CT-G20 Placebo
|
oral tablet of Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse events including serious Adverse events (Part I, Part II)
Time Frame: 46 days
|
46 days
|
Food effect as assessed by : PK parameters including Area under the concentration-time curve (AUC) and Maximum observed concentration (Cmax) (Part III)
Time Frame: Up to 48 hours after administration
|
Up to 48 hours after administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety parameters as assessed by: QT interval of ECG
Time Frame: 17 Days
|
17 Days
|
Safety parameters as assessed by: QTcF of ECG
Time Frame: 17 Days
|
17 Days
|
Safety parameters as assessed by: blood pressure of Vital signs
Time Frame: 17 Days
|
17 Days
|
Safety parameters as assessed by: pulse rate of Vital signs
Time Frame: 17 Days
|
17 Days
|
Safety parameters as assessed by: body temperature of Vital signs
Time Frame: 17 Days
|
17 Days
|
Safety parameters as assessed by: hematology of Clinical laboratory tests
Time Frame: 17 Days
|
17 Days
|
Safety parameters as assessed by: clinical chemistry
Time Frame: 17 Days
|
17 Days
|
PK parameters as assessed by : Area under the concentration-time curve (AUC)
Time Frame: 13 Days
|
13 Days
|
PK parameters as assessed by : Maximum observed concentration (Cmax)
Time Frame: 13 Days
|
13 Days
|
PK parameters as assessed by : Time to Cmax (tmax)
Time Frame: 13 Days
|
13 Days
|
PK parameters as assessed by : Terminal half-life time (t1/2)
Time Frame: 13 Days
|
13 Days
|
PD parameters as assessed by : Left ventricular ejection fraction (LVEF)
Time Frame: 17 Days
|
17 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: In-Jin Jang, Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 8, 2019
Primary Completion (Actual)
June 6, 2020
Study Completion (Actual)
June 6, 2020
Study Registration Dates
First Submitted
April 9, 2019
First Submitted That Met QC Criteria
April 16, 2019
First Posted (Actual)
April 18, 2019
Study Record Updates
Last Update Posted (Actual)
June 9, 2020
Last Update Submitted That Met QC Criteria
June 7, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- CT-G20 1.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on CT-G11
-
University of PittsburghTerminatedCarcinoma, Squamous Cell of Head and NeckUnited States
-
Northwell HealthHeartFlow, Inc.CompletedAngina, Stable Chest Pain
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Northwell HealthToshiba America Medical Systems, Inc.Enrolling by invitationCoronary Artery Disease | Chest Pain | Acute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
Ankara Yildirim Beyazıt UniversityCompletedPain | Shoulder SyndromeTurkey
-
Seoul National University Bundang HospitalGE Healthcare; National Research Foundation of KoreaCompletedAppendicitisKorea, Republic of
-
The University of Texas Health Science Center at...Recruiting
-
UMC UtrechtDutch Heart FoundationUnknown
-
Rigshospitalet, DenmarkRecruitingCardiovascular Diseases | Coronary Artery Disease | Heart Failure | Stroke | Acute Myocardial Infarction | Chest SyndromeDenmark